Interventional cardiology

CMS Grants Transitional Pass-Through (TPT) Payment for Shockwave’s Coronary IVL

Friday, June 11, 2021 - 9:03pm

In the July 2021 Update of the Hospital Outpatient Prospective Payment System (OPPS), CMS issued a new device transitional pass-through code (C1761) for use by hospitals to bill for Shockwave C2 Coronary IVL catheters.

Key Points: 
  • In the July 2021 Update of the Hospital Outpatient Prospective Payment System (OPPS), CMS issued a new device transitional pass-through code (C1761) for use by hospitals to bill for Shockwave C2 Coronary IVL catheters.
  • In addition, as part of the payment calculation, CMS announced that a customary deduction known as a device offset will not be applied to coronary stenting procedures involving coronary IVL.
  • The Shockwave C2 Coronary IVL device will be eligible for TPT payments for three years.
  • This announcement comes less than two months after CMS recommended Coronary IVL be eligible for incremental payment via a New Technology Add-on Payment (NTAP) as part of the Fiscal Year 2022 Hospital Inpatient Prospective Payment System (IPPS) Proposed Rule.

Insights on the Vascular Stents Global Market to 2026 - by Product Type, Material, Mode of Delivery, End-user and Region - ResearchAndMarkets.com

Friday, June 11, 2021 - 12:40pm

The global vascular stents market reached a value of US$ 9.4 Billion in 2020.

Key Points: 
  • The global vascular stents market reached a value of US$ 9.4 Billion in 2020.
  • Vascular stents are usually made of polyethylene, polypropylene or non-absorbable materials such as stainless steel or cobalt-chromium alloys.
  • Looking forward, the publisher expects the global vascular stents market to grow at a CAGR of 6.1% during 2021-2026.
  • Key Questions Answered in This Report:
    How has the global vascular stents market performed so far and how will it perform in the coming years?

Heart Pump Device Market by Product, Type, Therapy and Region - Global Forecast to 2026 - ResearchAndMarkets.com

Wednesday, June 9, 2021 - 3:34pm

The global heart pump device market is projected to reach USD 5.5 billion by 2026 from USD 2.1 billion in 2021, at a CAGR of 21.6% from 2021 to 2026.

Key Points: 
  • The global heart pump device market is projected to reach USD 5.5 billion by 2026 from USD 2.1 billion in 2021, at a CAGR of 21.6% from 2021 to 2026.
  • Ventricular assist devices are expected to hold the largest share of the heart pump device market, by product in 2021
    Based on products, the heart pump devices market is segmented into ventricular assist devices, intra- aortic balloon pumps, and total artificial hearts.
  • Implantable heart pump devices are expected to hold the largest share of the heart pump device market, by type in 2021
    Based on type, the market is segmented into implantable heart pump devices and extracorporeal heart pump devices.
  • Bridge-to-transplant is expected to hold the largest share of the heart pump device market, by therapy in 2021
    Based on therapy, the market is segmented into bridge-to-transplant (BTT), bridge-to-candidacy (BTC), destination therapy (DT), and other therapies.

AdjuCor Raises € 29 Million in Series B Funding Round for its Revolutionary Heart Assist Technology that Completely Avoids Blood Contact

Wednesday, June 9, 2021 - 12:20pm

MUNICH, Germany, June 9, 2021 /PRNewswire-PRWeb/ --AdjuCor is developing an implantable heart assist device that, contrary to all existing heart assist devices, has the capability to assist the heart while completely avoiding the complication-laden aspect of blood contact.

Key Points: 
  • MUNICH, Germany, June 9, 2021 /PRNewswire-PRWeb/ --AdjuCor is developing an implantable heart assist device that, contrary to all existing heart assist devices, has the capability to assist the heart while completely avoiding the complication-laden aspect of blood contact.
  • Securing the 29 million of this round and getting MitrAssist Holdings Limited on board are exactly what AdjuCor has been looking for to reach its goals".
  • It is implanted by a heart team (cardiologist and surgeon) within a few minutes on the beating heart without sutures.
  • It completely avoids blood contact and thereby any blood-related complications including strokes and bleeding an invaluable advantage that cannot be over-stated.

Leading Interventional Cardiologist Dr. Giora Weisz Joins Microbot Medical’s Scientific Advisory Board

Monday, June 7, 2021 - 12:00pm

HINGHAM, Mass., June 07, 2021 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) continues its ongoing commitment to strengthen and broaden its capabilities as Giora Weisz, MD joined the Companys Scientific Advisory Board (SAB).

Key Points: 
  • HINGHAM, Mass., June 07, 2021 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) continues its ongoing commitment to strengthen and broaden its capabilities as Giora Weisz, MD joined the Companys Scientific Advisory Board (SAB).
  • Dr. Weisz is a practicing interventional cardiologist and clinical researcher who has pioneered novel robotic-enhanced coronary interventions, as well as navigation and positioning technologies.
  • He was also the principal investigator of the multi-center pivotal study leading to the FDA approval of the system.
  • As a practicing interventional cardiologist, Dr. Weisz has particular interest in current and innovative technologies in cardiovascular medicine.

Abbott Confirms Capacity to Support Expanded Use of HeartMate 3™ Heart Pump

Thursday, June 3, 2021 - 12:00pm

Abbott is also supporting training and education programs for additional physicians who will now be offering Abbott's HeartMate 3 heart pumps to their patients.

Key Points: 
  • Abbott is also supporting training and education programs for additional physicians who will now be offering Abbott's HeartMate 3 heart pumps to their patients.
  • To support patients and their physicians, Abbott's HeartMate 3 heart pump is available to physicians and patients around the world in markets where the technology has been approved for use.
  • Abbott's HeartMate 3 heart pump is a small, implantable mechanical circulatory support device for advanced heart failure patients requiring either short- or long-term support who are awaiting a heart transplant or who are not candidates for heart transplantation.
  • In addition to extending the lives of patients with advanced heart failure, Abbott's HeartMate 3 heart pump can significantly improve quality of life and reduce adverse events.

Cardiovascular Systems, Inc. to Participate at the Raymond James Human Health Innovations Conference

Wednesday, June 2, 2021 - 12:00pm

Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today announced that management plans to present and host investor meetings at the Raymond James Human Health Innovations Conference on June 23rd.

Key Points: 
  • Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today announced that management plans to present and host investor meetings at the Raymond James Human Health Innovations Conference on June 23rd.
  • A webcast of the presentation will be made available on CSI's website.
  • Cardiovascular Systems, Inc., based in St. Paul, Minn., is a medical device company focused on developing and commercializing innovative solutions for treating vascular and coronary disease.
  • For additional information, please visit www.csi360.com and connect on Twitter @csi360.

Wissam N. Hoyek, MD, FACC, is recognized by Continental Who's Who

Friday, May 28, 2021 - 5:59pm

Board-certified Interventional Cardiologist Dr. Wissam N. Hoyek, has been practicing medicine for over 20 years.

Key Points: 
  • Board-certified Interventional Cardiologist Dr. Wissam N. Hoyek, has been practicing medicine for over 20 years.
  • He has extensive knowledge in all facets of his work, including interventional cardiology, catheterization, echo, and vascular, to name a few.
  • As the Founder of his private practice Wissam N. Hoyek MD Interventional Cardiology, he treats patients at 271 Mason Avenue in Staten Island, NY.
  • Dr. Hoyek is committed to providing the highest standard of healthcare at his private practice in his current position.

Worldwide Drug-Eluting Stents Industry to 2027 - Surge in Demand for Minimally Invasive Surgical Procedures is Driving Growth - ResearchAndMarkets.com

Tuesday, May 25, 2021 - 1:37pm

Drug-eluting stents (DES) are small cylindrical stents that aid in improving blood flow through arteries to heart by minimizing blockages.

Key Points: 
  • Drug-eluting stents (DES) are small cylindrical stents that aid in improving blood flow through arteries to heart by minimizing blockages.
  • Polymer-based drug-eluting coating stents are designed to allow consistent and controlled release of drug from stent surface into arteries.
  • Conversely, growth potential in emerging economies is expected to create lucrative opportunities for the market growth during the forecast period.
  • Profiles and growth strategies of key players are thoroughly analyzed to understand the competitive outlook of the global market.

amg International GmbH, a Q3 Medical Devices Ltd Company, Receives European CE Mark Approval for UNITY-B™ Biodegradable Stent

Monday, May 24, 2021 - 10:38pm

The Company announced that it has received CE Mark approval for its second fully biodegradable product, the UNITY-B balloon expandable biodegradable biliary stent (BEBS) for endoscopic use.

Key Points: 
  • The Company announced that it has received CE Mark approval for its second fully biodegradable product, the UNITY-B balloon expandable biodegradable biliary stent (BEBS) for endoscopic use.
  • The UNITY-B Biodegradable implant was developed as a complimentary biodegradable metallic stent to amg's ARCHIMEDES biodegradable pancreaticobiliary stent, which is currently available in fast, medium, and long-lasting degradation profiles.
  • ARCHIMEDES obtained CE mark approval in 2018 and was subsequently launched through a global distribution partnership with Medtronic.
  • "The CE mark approval of the UNITY-B stent represents yet another milestone for amg International and all the companies of Q3 Medical and our mission to 'Create Value By Helping People'.